Texas is currently home to 4888 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Child and Adolescent Registry for Participants With Narcolepsy
Recruiting
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com.... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
08/13/2024
Locations: Texas Children's Hospital (Baylor College of Medicine), Houston, Texas
Conditions: Narcolepsy
Rapamycin - Effects on Alzheimer's and Cognitive Health
Recruiting
This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).
Gender:
ALL
Ages:
Between 55 years and 89 years
Trial Updated:
08/12/2024
Locations: Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas
Conditions: Mild Cognitive Impairment, Alzheimer Disease
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Recruiting
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Pancreatic Ductal Adenocarcinoma
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
Recruiting
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/09/2024
Locations: ICON Early Phase Services, LLC, San Antonio, Texas
Conditions: Healthy
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
Recruiting
This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol protocol).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/09/2024
Locations: Sun Research Institute, San Antonio, Texas
Conditions: Iron Deficiency Anemia
Erector Spinae Regional Anesthesia for Pain Control
Recruiting
Interventional study to use erector spinae plane block (ESPB) on diagnoses of posterior or lateral rib fractures, vertebral fractures, pancreatitis, pancreatic cancer, renal colic, and back pain for multimodal pain therapy to determine its assistance with pain relief as well as the patient's use of opiates after block completion
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: University Hospital, San Antonio, Texas
Conditions: Pain Management
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Recruiting
This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumor
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
Recruiting
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).
Gender:
ALL
Ages:
10 years and below
Trial Updated:
08/08/2024
Locations: University of Texas Southwestern / Children's Health, Dallas, Texas
Conditions: Cystic Fibrosis
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Recruiting
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
Normative Database and Test-Retest Reliability for BrainCheck Assessments
Recruiting
The purpose of this study is to collect normative test values and demographic information for normative and referential data for a rapid, portable, computerized neurocognitive testing device from healthy adults 50 and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/07/2024
Locations: BrainCheck, Austin, Texas
Conditions: Cognitive Change, Cognitive Decline, Cognitive Deterioration, Neurocognitive Deficit
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Recruiting
This is a Phase 1, open-label, dose-escalation trial using standard 3+3 dose-escalation design in patients with advanced malignant solid tumors. All patients within a given dose level cohort will be treated with the same dose schedule of VG2025, administered as intratumoral injections at Day 1 and Day 15 biweekly at each treatment cycle (monotherapy cohorts 1-4 and combination cohort 1) and on day 1 and either day 2 or day 3 at the first 2 cycles followed by day 1 only at subsequent cycles (comb... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: MD Anderson, Houston, Texas
Conditions: Solid Tumor
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
Recruiting
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2024
Locations: Mays Cancer Center, UT Health San Antonio, San Antonio, Texas
Conditions: Glioblastoma